Evidence map›Paper›PMID 35320821›Full record

ArticlePloS one2022

Persisting olfactory dysfunction in post-COVID-19 is associated with gustatory impairment: Results from chemosensitive testing eight months after the acute infection.

Constantin A Hintschich, René Fischer, Thomas Hummel, Jürgen J Wenzel, Christopher Bohr, Veronika Vielsmeier

3 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05445921 phase1 / phase2completednot on this map

Stellate Ganglion Block for the Treatment of COVID-19-Induced Olfactory Dysfunction: A Prospective Pilot Study

TypeinterventionalSponsorWashington University School of MedicineRan2022 to 2022Enrolled20ConditionsAnosmia, Hyposmia, Parosmia, Olfactory DisorderArmsStellate Ganglion Block
NCT06055270 phase3unknown statusnot on this mapstarted 2024, after this paper: background citation

Stellate Ganglion Block With Lidocaine for the Treatment of COVID-19-Induced Parosmia: Double-Blinded, Placebo-Controlled Randomized Clinical Trial

TypeinterventionalSponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sRan2024 to 2026Enrolled44ConditionsParosmiaArmsStellate Ganglion Block, Placebo
NCT06253806 phase2completednot on this mapstarted 2023, after this paper: background citation

Stellate Ganglion Block for the Treatment of COVID-19-Induced Parosmia: Double-Blinded, Placebo-Controlled Randomized Clinical Trial

TypeinterventionalSponsorWashington University School of MedicineRan2023 to 2024Enrolled48ConditionsCOVID-19-Induced ParosmiaArmsStellate Ganglion Block, Placebo Sham Injection
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Long COVID: An approach to clinical assessment and management in primary care.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2023
    Article
  12. Long-term Consequences of COVID-19: Chemosensory Disorders.Current allergy and asthma reports · 2023
    Review
  13. COVID-19 Oral Sequelae: Persistent Gustatory and Saliva Secretory Dysfunctions after Recovery from COVID-19.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2023
    Review
  14. Review
  15. Author's reply to the Letter to the Editor "The study of olfactory dysfunction in SARS-CoV-2 variants".European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2022
    Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Constantin A HintschichDepartment of Otorhinolaryngology, Regensburg University Hospital, Regensburg, Germany.ORCID 0000-0002-5500-600X
René FischerDepartment of Otorhinolaryngology, Regensburg University Hospital, Regensburg, Germany.
Thomas HummelSmell & Taste Clinic, Department of Otorhinolaryngology, TU Dresden, Dresden, Germany.
Jürgen J WenzelInstitute of Clinical Microbiology and Hygiene, Regensburg University Hospital, Regensburg, Germany.
Christopher BohrDepartment of Otorhinolaryngology, Regensburg University Hospital, Regensburg, Germany.
Veronika VielsmeierDepartment of Otorhinolaryngology, Regensburg University Hospital, Regensburg, Germany.
University Hospital Regensburg · DETechnische Universität Dresden · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Olfactory and gustatory disorders are prominent symptoms of acute COVID-19. Although both senses recover in many patients within weeks to months, persistency has been described in up to 60%. However up to now most reports on the course of chemosensitive disorders after COVID-19 are not based on psychophysical testing but only on subjective patients' ratings. In this study we assessed both olfaction and gustation using psychophysical tests eight months after COVID-19. Validated psychophysical testing revealed hyposmia in 18% and hypogeusia in even 32% of 303 included patients. This shows that olfactory and especially gustatory disorders have to be seen as important chronic symptoms post-COVID-19. The high prevalence of gustatory dysfunction indicates that gustatory function does not recover or might even deteriorate in the months following the acute infection.

Indexed as

TasteCOVID-19Feeding and Eating DisordersFemaleHumansMaleMiddle AgedOlfaction DisordersPost-Acute COVID-19 SyndromeSurveys and QuestionnairesTaste Threshold

Identifiers

PMID35320821
PMCPMC8942205
OpenAlexW4220722908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.